Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan Everest Medicines Limited Aug 08, 2025 18:09 HKT/SGT Read More
雲頂新耀耐賦康(R)擴產獲批 亞洲全域完全批准雙突破 加速邁向50億銷售峰值 Everest Medicines Limited Aug 08, 2025 18:09 HKT/SGT Read More
NEFECON(R) Receives NMPA Approval for Production Expansion in China,as Everest Medicines Accelerates Accessibility and Capacity Efforts Everest Medicines Limited Aug 05, 2025 10:21 HKT/SGT Read More
全球首個IgA腎病對因治療藥物耐賦康®擴產獲批 雲頂新耀加速提升可及性與產能佈局 Everest Medicines Limited Aug 05, 2025 10:21 HKT/SGT Read More
全球首个IgA肾病对因治疗药物耐赋康®扩产获批 云顶新耀加速提升可及性与产能布局 Everest Medicines Limited Aug 05, 2025 10:21 HKT/SGT Read More
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies Everest Medicines Limited Aug 02, 2025 00:02 HKT/SGT Read More
雲頂新耀宣佈增加對I-Mab的戰略投資 開發自研新一代腫瘤免疫療法的全球價值 Everest Medicines Limited Aug 01, 2025 23:48 HKT/SGT Read More
云顶新耀宣布增加对I-Mab的战略投资 开发自研新一代肿瘤免疫疗法的全球价值 Everest Medicines Limited Aug 01, 2025 23:45 HKT/SGT Read More
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC Eisai Jul 31, 2025 08:30 HKT/SGT Read More
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease Eisai Jul 31, 2025 08:20 HKT/SGT Read More
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 Eisai Jul 31, 2025 08:10 HKT/SGT Read More
Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence Biolog, Inc Jul 29, 2025 16:00 HKT/SGT Read More
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma Eisai Jul 29, 2025 08:01 HKT/SGT Read More
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China China Medical System Holdings Limited Jul 29, 2025 05:00 JST Read More
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China China Medical System Holdings Limited Jul 29, 2025 04:00 HKT/SGT Read More
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China Essex Bio-Technology Limited Jul 25, 2025 11:52 JST Read More
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million Everest Medicines Limited Jul 25, 2025 11:01 JST Read More